Literature DB >> 12533646

Hepatocellular carcinoma treated with radio-frequency ablation: spectrum of imaging findings.

Seung Kwon Kim1, Hyo Keun Lim, Young Han Kim, Won Jae Lee, Soon Jin Lee, Seung Hoon Kim, Jae Hoon Lim, Soo Ah Kim.   

Abstract

Contrast material-enhanced Doppler or gray-scale harmonic ultrasonography (US) may help determine the completeness or long-term therapeutic efficacy of radio-frequency (RF) ablation of hepatocellular carcinoma (HCC). Successfully treated HCC is devoid of vascularity at color or power Doppler US. When the tumor is not completely treated, residual viable tumor can be detected. These contrast-enhanced US techniques may also help identify residual tumor when performed during repeat RF ablation, when accurate localization of viable tumor is needed. To date, contrast-enhanced computed tomography (CT) has been the most widely used imaging modality in the evaluation of therapeutic response after RF ablation of HCC. At follow-up CT, successfully ablated lesions appear as low-attenuation areas with no foci of contrast enhancement either within or at the periphery of the treated lesion, whereas any foci of enhancement indicate residual or recurrent tumor. Reactive hyperemia in tissue surrounding the ablated lesion, iatrogenic arterioportal shunting, and small intralesional air pockets are frequently seen at immediate follow-up CT. Gadolinium-enhanced dynamic magnetic resonance imaging is also useful in assessing therapeutic response following RF ablation of HCC, particularly when CT findings are inconclusive. Familiarity with these imaging findings is helpful in this setting. Copyright RSNA, 2003.

Entities:  

Mesh:

Year:  2003        PMID: 12533646     DOI: 10.1148/rg.231025055

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  26 in total

Review 1.  Hepatic perfusion disorders: etiopathogenesis and related diseases.

Authors:  Jin-Lin Tian; Jin-Shan Zhang
Journal:  World J Gastroenterol       Date:  2006-05-28       Impact factor: 5.742

Review 2.  Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI.

Authors:  Yasunori Minami; Naoshi Nishida; Masatoshi Kudo
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 3.  Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma.

Authors:  Shashi B Paul; Hanish Sharma
Journal:  J Clin Exp Hepatol       Date:  2014-05-24

4.  Role of contrast-enhanced ultrasound in follow-up assessment after ablation for hepatocellular carcinoma.

Authors:  Shu-Guang Zheng; Hui-Xiong Xu; Ming-De Lu; Xiao-Yan Xie; Zuo-Feng Xu; Guang-Jian Liu; Lin-Na Liu
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

5.  Fusion imaging with contrast-enhanced ultrasonography for evaluating the early therapeutic efficacy of radiofrequency ablation for small hypervascular hepatocellular carcinomas with iso-echoic or unclear margins on conventional ultrasonography.

Authors:  Shuhei Nishigori; Kazushi Numata; Kuniyasu Irie; Hiroyuki Fukuda; Makoto Chuma; Shin Maeda
Journal:  J Med Ultrason (2001)       Date:  2018-01-23       Impact factor: 1.314

Review 6.  Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.

Authors:  Ania Kielar; Kathryn J Fowler; Sara Lewis; Vahid Yaghmai; Frank H Miller; Hooman Yarmohammadi; Charles Kim; Victoria Chernyak; Takeshi Yokoo; Jeffrey Meyer; Isabel Newton; Richard K Do
Journal:  Abdom Radiol (NY)       Date:  2018-01

Review 7.  Imaging Modalities for Assessment of Treatment Response to Nonsurgical Hepatocellular Carcinoma Therapy: Contrast-Enhanced US, CT, and MRI.

Authors:  Yasunori Minami; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2015-04-08       Impact factor: 11.740

8.  Radiofrequency ablation of renal tumours: diagnostic accuracy of contrast-enhanced ultrasound for early detection of residual tumour.

Authors:  Christine Hoeffel; Maud Pousset; Marc-Olivier Timsit; Caroline Elie; Arnaud Méjean; Samuel Merran; François Tranquart; Ahmed Khairoune; Dominique Joly; Stéphane Richard; Olivier Hélénon; Jean-Michel Correas
Journal:  Eur Radiol       Date:  2010-03-04       Impact factor: 5.315

Review 9.  MRI of hepatocellular carcinoma: an update of current practices.

Authors:  Hina Arif-Tiwari; Bobby Kalb; Surya Chundru; Puneet Sharma; James Costello; Rainner W Guessner; Diego R Martin
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

10.  Contrast-enhanced ultrasonography (CEUS) immediately after percutaneous ablation of hepatocellular carcinoma.

Authors:  A Gallotti; M D'Onofrio; A Ruzzenente; E Martone; R De Robertis; A Guglielmi; R Pozzi Mucelli
Journal:  Radiol Med       Date:  2009-09-05       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.